Vascular enhancement pattern of mass in computed tomography may predict chemo-responsiveness in advanced pancreatic cancer

详细信息    查看全文

• 作者：Shin Il Kim^a ; ² ; Jun Young Shin^a ; ² ; Jin-Seok Park^a ; Seok Jeong^a ; ^b ; ¹ ; ^{inos@inha.ac.kr} ; Yong Sun Jeon^c ; Moon Han Choi^d ; Hyun Jong Choi^d ; Jong Ho Moon^d ; Jae Chul Hwang^e ; Min Jae Yang^e ; Byoung Moo Yoo^e ; Jin Hong Kim^e ; Hyun Woo Lee^f ; Chang-Il Kwon^g ; Don Haeng Lee^a ; ^b ; ¹ ; ^{LDH@inha.ac.kr}
• 关键词：Pancreatic cancer ; Contrast-enhanced CT ; Chemotherapy ; Vascularity ; Desmoplastic reaction
• 刊名：Pancreatology
• 出版年：2017
• 出版时间：January-February 2017
• 年：2017
• 卷：17
• 期：1
• 页码：103-108
• 全文大小：858 K
• 卷排序：17

文摘

Chemo-responsiveness in pancreatic cancer is known to be dependent on fibrosis and vascularity. The purpose of this study was to assess vascular enhancement in advanced pancreatic adenocarcinoma with or without liver metastasis in computed tomography (CT) and to analyze the correlation between enhancement patterns and chemo-responsiveness.MethodsPatients were assigned to either a responder group (partial response or stable disease) or a non-responder group (progressive disease) according to chemo-responsiveness assessed by CT before and after gemcitabine-based chemotherapy. Hounsefield unit (HU) was measured in pancreatic mass and the largest metastatic liver mass using region of interest (ROI). HU differences (ΔHU) between arterial and pre-contrast phase were calculated.ResultsOf the 101 study subjects, 78(77.2%) were assigned to the pancreas responder group {mean ΔHU (±SD), 36.7(±21.6)} and 23(22.8%) to the pancreas non-responder group {mean ΔHU (±SD), 20.6(±9.9)} (p = 0.001 for ΔHUs). Of the 46 study subjects with liver metastasis, 25(54.3%) were assigned to the liver metastasis responder group {mean ΔHU (±SD), 36.9(±21.0} and 21(45.7%) to the liver metastasis non-responder group {mean ΔHU (±SD), 17.1 (±24.0)}, (p = 0.005 for ΔHUs).ConclusionCT determined mass vascular enhancement patterns may predict chemoresponse in advanced pancreatic cancer.